<p><strong>在成功完成第一阶段风湿病学测试后，Skye Salud 进入初级护理的第二阶段评估。</strong></p>
<p>, /PRNewswire/ -- Brand Engagement Network, Inc. (Nasdaq: BNAI) (&#34;BEN&#34;)，一家为人工智能的参与层提供企业级人工智能解决方案的供应商，今天宣布 Skye Salud 进入其在墨西哥的临床评估计划第二阶段。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2777074/Brand_Engagement_Network_LOGO.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2777074/Brand_Engagement_Network_LOGO.jpg"/></p>
<p>Skye Salud 是一个由 BEN、Grupo Skye 和 KNOBLOCH 信息集团合作开发的人工智能驱动的医学证据平台，利用可信的医学文献、临床指南和其他权威来源来支持基于证据的临床信息检索。</p>
<p>该项目结合了 BEN 的企业级人工智能能力、Grupo Skye 在拉丁美洲的人工智能创新领导地位，以及 KNOBLOCH 信息集团在墨西哥医疗社区的长期存在和可信关系。三方共同评估人工智能驱动的可信医学证据访问如何帮助改善墨西哥和拉丁美洲医疗环境中的临床信息获取。</p>
<p>第二阶段评估是在控制评估环境中成功完成第一阶段风湿病学测试后进行的。初步评估评估了平台在特定专业临床场景中的表现、证据可追溯性、响应质量和来源透明度。</p>
<p>基于这些结果，第二阶段评估将扩展测试到初级护理用例，平台将在更广泛的临床主题和医生信息需求中进行评估。扩展评估包括针对墨西哥医疗环境优化的西班牙语临床内容。</p>
<p>墨西哥是拉丁美洲最大的医疗市场之一，为评估大规模的人工智能驱动的可信医学证据访问创造了重要机会。将评估项目扩展到初级护理旨在提供有关平台性能、内容覆盖、可用性和未来发展机会的额外见解。</p>
<p>该项目反映了 BEN 在开发适用于受监管行业的企业级人工智能解决方案的更广泛战略，在这些行业中，准确性、透明度、问责制和人际互动至关重要。</p>
<p>第一阶段风湿病学测试是在 Skye Salud 的首席医学信息官兼 BEN 董事会成员 Ruy Carrasco 博士的指导下进行的。评估重点是评估平台生成基于可信医学证据来源的准确引用响应的能力。</p>
<p>&#34;完成我们的第一阶段风湿病学评估代表了 Skye Salud 项目的一个重要里程碑，&#34; BEN 的首席执行官兼联合创始人 Tyler Luck 说。&#34;第一阶段评估提供了有关平台性能、证据可追溯性和风湿病学用例中响应质量的宝贵见解。随着我们进入第二阶段，我们将评估扩展到初级护理，以评估更广泛的临床问题和用例中的性能。&#34;</p>
<p>&#34;我们的重点仍然是测试、验证和持续改进，&#34; Luck 继续说道。&#34;BEN、Grupo Skye 和 KNOBLOCH 信息集团之间的合作创造了一个独特的机会，以评估如何通过人工智能更高效地呈现可信医学证据，同时保持透明度、问责制和严格的证据标准。通过这些评估生成的见解将有助于指导未来平台的发展和潜在的商业化机会。&#34;</p>
<p>&#34;在风湿病学领域的初步试点作为验证平台响应架构的关键基线，特别是在临床严谨性和证据可追溯性方面，&#34; Skye Salud 的首席医学信息官 Ruy Carrasco 博士指出。</p>
<p>&#34;将这一评估框架扩展到初级护理允许在更异质的临床表现范围内对性能指标进行压力测试。至关重要的是，这一扩展将在不妥协第一阶段测试期间建立的严格证据阈值或来源透明度协议的情况下进行。&#34;</p>
<p>第二阶段初级护理评估具有双重战略目的：评估平台在更广泛护理场景中的临床覆盖和证据支持能力，同时生成可操作的见解，以指导未来产品开发和商业化规划。</p>
<p>根据未来评估结果、监管考虑和商业协议，BEN、Grupo Skye、KNOBLOCH 信息集团及其他医疗生态系统参与者可能会探索扩大临床覆盖、扩展西班牙语医学内容以及评估该平台在墨西哥和拉丁美洲医疗环境中的潜在未来应用的机会。</p>
<p><strong>附加信息</strong></p>
<p>有关初步 Skye Salud 公告和 BEN、Grupo Skye 及 KNOBLOCH 信息集团医疗倡议的更多信息，请访问公司的官方网站。</p>
<p>https://brandengagementnetwork.com/newsroom/knobloch-information-group-ben-and-skye-inteligencia-latam-form-skye-salud-to-modernize-healthcare-in-mexico-with-sovereign-ai</p>
<p><strong>关于 KNOBLOCH 信息集团</strong></p>
<p>KNOBLOCH 信息集团是墨西哥领先的医疗组织，长期以来通过医学教育、科学交流和医疗创新倡议支持医疗专业人员。通过参与 Skye Salud 评估项目，KNOBLOCH 信息集团提供医疗市场洞察和临床参与专业知识，帮助指导平台在更广泛的医学用例中的持续评估。</p>
<p><strong>关于 Brand Engagement Network, Inc.</strong> (Nasdaq: BNAI)</p>
<p>品牌参与网络公司（&#34;BEN&#34;）构建了安全的企业级人工智能，专注于人工智能的参与层，在这里人们与系统互动并发生行动。BEN 的专有参与语言模型（ELM™）驱动的技术使得对话式人工智能互动能够将人类意图与组织数据、工作流程和现实世界结果连接起来。BEN 的人工智能在安全的闭环环境中运行，使用经过批准的组织数据，并内置治理和合规控制。有关更多信息，请访问品牌参与网络。</p>
<p><strong>关于 Skye Salud</strong></p>
<p>Skye Salud 是一个基于人工智能的医学证据平台，目前正在评估其提供基于同行评审文献、临床指南和其他可信医学来源的证据基础响应的能力。该平台旨在通过对话式人工智能体验帮助组织和呈现临床信息，同时保持对支持来源的透明性和可追溯性。</p>
<p><strong>关于 Grupo Skye</strong></p>
<p>Grupo Skye 是一家总部位于墨西哥的人工智能控股公司，专注于在拉丁美洲执行企业和政府的人工智能项目。它是 Skye Inteligencia LATAM 的母公司，并在 Skye Salud（一家专注于医疗保健的人工智能解决方案公司）中保持平等的股权利益。</p>
<p><strong>媒体联系</strong></p>
<p>amy@beninc.ai</p>
<p><strong>投资者关系</strong></p>
<p>investors@beninc.ai</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明通常与未来事件或品牌参与网络公司（&#34;BEN&#34;）的未来财务或运营表现相关，可能包括但不限于关于 Skye Salud 的预期能力、好处、采用、商业化、扩展、市场机会和未来发展的声明；条件覆盖的扩展、医生的采用和平台的利用；在医疗保健环境中潜在的未来部署，包括初级护理和药房用例；在墨西哥和拉丁美洲的扩展机会；以及 BEN 执行其增长战略和在受监管行业中部署其技术的能力。这些前瞻性声明基于当前的期望、估计、预测和预测，以及管理层的信念和假设，并受到多种风险、不确定性和其他因素的影响，这些因素可能导致实际结果与这些声明所表达或暗示的结果有重大差异。这些风险和不确定性包括但不限于市场对 BEN 产品和服务的接受度；成功开发、部署和商业化基于人工智能的解决方案的能力；客户的采用和留存；监管发展；竞争压力；第三方技术和合作伙伴的可用性和表现；一般经济、商业和市场条件；以及 BEN 在美国证券交易委员会（&#34;SEC&#34;）的文件中不时描述的其他风险，包括其最近的 10-K 表格年度报告、10-Q 表格季度报告和 8-K 表格当前报告。读者被提醒不要对前瞻性声明过度依赖，这些声明仅在作出时有效。除非法律要求，BEN 没有义务更新、修订或公开发布任何对这些前瞻性声明的修订结果，以反映本新闻稿日期后的事件或情况。</p>
<p>来源：品牌参与网络公司（BEN）</p>

BNAI

<p>品牌参与网络（BNAI）宣布，由 Grupo Skye 和 KNOBLOCH 信息集团合作开发的人工智能医疗证据平台 Skye Salud 已进入墨西哥的第二阶段临床评估。在成功完成第一阶段风湿病学测试后，第二阶段试验扩展到初级护理，以评估在更广泛的临床主题和西班牙语内容中的表现，旨在改善拉丁美洲对可信医疗证据的获取</p>

<p><strong>Following successful Phase 1 rheumatology testing, Skye Salud advances to Phase 2 evaluation in primary care.</strong></p>
<div class="lb-trans"><p><strong>在成功完成第一阶段风湿病学测试后，Skye Salud 进入初级护理的第二阶段评估。</strong></p>
</div><p>, /PRNewswire/ -- Brand Engagement Network, Inc. (Nasdaq: BNAI) (&#34;BEN&#34;), a provider of enterprise-grade artificial intelligence solutions for the engagement layer of AI, today announced the advancement of Skye Salud to Phase 2 of its clinical evaluation program in Mexico.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Brand Engagement Network, Inc. (Nasdaq: BNAI) (&#34;BEN&#34;)，一家为人工智能的参与层提供企业级人工智能解决方案的供应商，今天宣布 Skye Salud 进入其在墨西哥的临床评估计划第二阶段。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2777074/Brand_Engagement_Network_LOGO.jpg" alt="" original-src="https://mma.prnewswire.com/media/2777074/Brand_Engagement_Network_LOGO.jpg"/></p>
<p>Developed through a collaboration among BEN, Grupo Skye, and KNOBLOCH Information Group, Skye Salud is an AI-powered medical evidence platform that leverages trusted medical literature, clinical guidelines, and other authoritative sources to support evidence-based clinical information retrieval.</p>
<div class="lb-trans"><p>Skye Salud 是一个由 BEN、Grupo Skye 和 KNOBLOCH 信息集团合作开发的人工智能驱动的医学证据平台，利用可信的医学文献、临床指南和其他权威来源来支持基于证据的临床信息检索。</p>
</div><p>The initiative combines BEN's enterprise-grade AI capabilities, Grupo Skye's leadership in AI innovation across Latin America, and KNOBLOCH Information Group's longstanding presence and trusted relationships within Mexico's healthcare community. Together, the organizations are evaluating how AI-powered access to trusted medical evidence may help improve access to clinical information across healthcare settings in Mexico and Latin America.</p>
<div class="lb-trans"><p>该项目结合了 BEN 的企业级人工智能能力、Grupo Skye 在拉丁美洲的人工智能创新领导地位，以及 KNOBLOCH 信息集团在墨西哥医疗社区的长期存在和可信关系。三方共同评估人工智能驱动的可信医学证据访问如何帮助改善墨西哥和拉丁美洲医疗环境中的临床信息获取。</p>
</div><p>The Phase 2 evaluation follows the successful completion of Phase 1 rheumatology testing conducted in a controlled evaluation environment. The initial evaluation assessed platform performance across specialty-specific clinical scenarios, evidence traceability, response quality and source transparency.</p>
<div class="lb-trans"><p>第二阶段评估是在控制评估环境中成功完成第一阶段风湿病学测试后进行的。初步评估评估了平台在特定专业临床场景中的表现、证据可追溯性、响应质量和来源透明度。</p>
</div><p>Building on those results, the Phase 2 evaluation will expand testing into primary care use cases, where the platform will be assessed across a broader range of clinical topics and physician information needs. The expanded evaluation includes Spanish-language clinical content optimized for the Mexican healthcare environment.</p>
<div class="lb-trans"><p>基于这些结果，第二阶段评估将扩展测试到初级护理用例，平台将在更广泛的临床主题和医生信息需求中进行评估。扩展评估包括针对墨西哥医疗环境优化的西班牙语临床内容。</p>
</div><p>Mexico represents one of the largest healthcare markets in Latin America, creating a significant opportunity to evaluate AI-enabled access to trusted medical evidence at scale. The expansion of the evaluation program into primary care is intended to provide additional insight into platform performance, content coverage, usability, and future development opportunities.</p>
<div class="lb-trans"><p>墨西哥是拉丁美洲最大的医疗市场之一，为评估大规模的人工智能驱动的可信医学证据访问创造了重要机会。将评估项目扩展到初级护理旨在提供有关平台性能、内容覆盖、可用性和未来发展机会的额外见解。</p>
</div><p>The initiative reflects BEN's broader strategy of developing governed, enterprise-grade AI solutions for regulated industries where accuracy, transparency, accountability, and human engagement are critical.</p>
<div class="lb-trans"><p>该项目反映了 BEN 在开发适用于受监管行业的企业级人工智能解决方案的更广泛战略，在这些行业中，准确性、透明度、问责制和人际互动至关重要。</p>
</div><p>Phase 1 rheumatology testing was conducted under the guidance of Dr. Ruy Carrasco, Chief Medical Information Officer of Skye Salud and BEN Board Member. The evaluation focused on assessing the platform's ability to generate accurate, cited responses grounded in trusted medical evidence sources.</p>
<div class="lb-trans"><p>第一阶段风湿病学测试是在 Skye Salud 的首席医学信息官兼 BEN 董事会成员 Ruy Carrasco 博士的指导下进行的。评估重点是评估平台生成基于可信医学证据来源的准确引用响应的能力。</p>
</div><p>&#34;Completion of our Phase 1 rheumatology evaluation represents an important milestone for the Skye Salud initiative,&#34; said Tyler Luck, Chief Executive Officer and Co-Founder of BEN. &#34;The Phase 1 evaluation provided valuable insight into platform performance, evidence traceability and response quality across rheumatology use cases. As we enter Phase 2, we are expanding the evaluation into primary care to assess performance across a broader range of clinical questions and use cases.&#34;</p>
<div class="lb-trans"><p>&#34;完成我们的第一阶段风湿病学评估代表了 Skye Salud 项目的一个重要里程碑，&#34; BEN 的首席执行官兼联合创始人 Tyler Luck 说。&#34;第一阶段评估提供了有关平台性能、证据可追溯性和风湿病学用例中响应质量的宝贵见解。随着我们进入第二阶段，我们将评估扩展到初级护理，以评估更广泛的临床问题和用例中的性能。&#34;</p>
</div><p>&#34;Our focus remains on testing, validation and continuous improvement,&#34; Luck continued. &#34;The collaboration among BEN, Grupo Skye and KNOBLOCH Information Group creates a unique opportunity to evaluate how trusted medical evidence can be surfaced more efficiently through AI while maintaining transparency, accountability and rigorous evidence standards. Insights generated through these evaluations will help guide future platform development and potential commercialization opportunities.&#34;</p>
<div class="lb-trans"><p>&#34;我们的重点仍然是测试、验证和持续改进，&#34; Luck 继续说道。&#34;BEN、Grupo Skye 和 KNOBLOCH 信息集团之间的合作创造了一个独特的机会，以评估如何通过人工智能更高效地呈现可信医学证据，同时保持透明度、问责制和严格的证据标准。通过这些评估生成的见解将有助于指导未来平台的发展和潜在的商业化机会。&#34;</p>
</div><p>&#34;The initial pilot within the domain of Rheumatology served as a critical baseline to validate the platform's response architecture, specifically concerning clinical rigor and evidence tractability,&#34; noted Dr. Ruy Carrasco, Chief Medical Information Officer of Skye Salud.</p>
<div class="lb-trans"><p>&#34;在风湿病学领域的初步试点作为验证平台响应架构的关键基线，特别是在临床严谨性和证据可追溯性方面，&#34; Skye Salud 的首席医学信息官 Ruy Carrasco 博士指出。</p>
</div><p>&#34;Extending this evaluation framework into Primary Care allows for the stress-testing of performance metrics across a more heterogeneous spectrum of clinical presentations. Crucially, this expansion will be executed without compromising the stringent evidence thresholds or the source transparency protocols established during the foundational Phase 1 testing.&#34;</p>
<div class="lb-trans"><p>&#34;将这一评估框架扩展到初级护理允许在更异质的临床表现范围内对性能指标进行压力测试。至关重要的是，这一扩展将在不妥协第一阶段测试期间建立的严格证据阈值或来源透明度协议的情况下进行。&#34;</p>
</div><p>The Phase 2 primary care evaluation serves a dual strategic purpose: assessing the platform's clinical coverage and evidence-support capabilities across broader care scenarios while generating actionable insights to inform future product development and commercialization planning.</p>
<div class="lb-trans"><p>第二阶段初级护理评估具有双重战略目的：评估平台在更广泛护理场景中的临床覆盖和证据支持能力，同时生成可操作的见解，以指导未来产品开发和商业化规划。</p>
</div><p>Subject to future evaluation results, regulatory considerations and commercial agreements, BEN, Grupo Skye, KNOBLOCH Information Group and other healthcare ecosystem participants may explore opportunities to broaden clinical coverage, expand Spanish-language medical content and evaluate potential future applications of the platform within healthcare settings across Mexico and Latin America.</p>
<div class="lb-trans"><p>根据未来评估结果、监管考虑和商业协议，BEN、Grupo Skye、KNOBLOCH 信息集团及其他医疗生态系统参与者可能会探索扩大临床覆盖、扩展西班牙语医学内容以及评估该平台在墨西哥和拉丁美洲医疗环境中的潜在未来应用的机会。</p>
</div><p><strong>Additional Information</strong></p>
<div class="lb-trans"><p><strong>附加信息</strong></p>
</div><p>For more information about the initial Skye Salud announcement and the formation of the BEN, Grupo Skye and KNOBLOCH Information Group healthcare initiative, please visit the Company's website.</p>
<div class="lb-trans"><p>有关初步 Skye Salud 公告和 BEN、Grupo Skye 及 KNOBLOCH 信息集团医疗倡议的更多信息，请访问公司的官方网站。</p>
</div><p>https://brandengagementnetwork.com/newsroom/knobloch-information-group-ben-and-skye-inteligencia-latam-form-skye-salud-to-modernize-healthcare-in-mexico-with-sovereign-ai</p>
<div class="lb-trans"><p>https://brandengagementnetwork.com/newsroom/knobloch-information-group-ben-and-skye-inteligencia-latam-form-skye-salud-to-modernize-healthcare-in-mexico-with-sovereign-ai</p>
</div><p><strong>About KNOBLOCH Information Group</strong></p>
<div class="lb-trans"><p><strong>关于 KNOBLOCH 信息集团</strong></p>
</div><p>KNOBLOCH Information Group is a leading healthcare organization in Mexico with a long history of supporting healthcare professionals through medical education, scientific exchange and healthcare innovation initiatives. Through its participation in the Skye Salud evaluation program, KNOBLOCH Information Group provides healthcare market insight and clinical engagement expertise that helps inform the continued evaluation of the platform across a broader range of medical use cases.</p>
<div class="lb-trans"><p>KNOBLOCH 信息集团是墨西哥领先的医疗组织，长期以来通过医学教育、科学交流和医疗创新倡议支持医疗专业人员。通过参与 Skye Salud 评估项目，KNOBLOCH 信息集团提供医疗市场洞察和临床参与专业知识，帮助指导平台在更广泛的医学用例中的持续评估。</p>
</div><p><strong>About Brand Engagement Network, Inc.</strong> (Nasdaq: BNAI)</p>
<div class="lb-trans"><p><strong>关于 Brand Engagement Network, Inc.</strong> (Nasdaq: BNAI)</p>
</div><p>Brand Engagement Network, Inc. (&#34;BEN&#34;) builds secure, enterprise-grade artificial intelligence for the engagement layer of AI, where people interact with systems and actions occur. Powered by BEN's proprietary Engagement Language Model (ELM™), BEN's technology enables conversational AI interactions that connect human intent to organizational data, workflows and real-world outcomes. BEN's AI operates within secure closed-loop environments using approved organizational data and built-in governance and compliance controls. For more information, visit Brand Engagement Network.</p>
<div class="lb-trans"><p>品牌参与网络公司（&#34;BEN&#34;）构建了安全的企业级人工智能，专注于人工智能的参与层，在这里人们与系统互动并发生行动。BEN 的专有参与语言模型（ELM™）驱动的技术使得对话式人工智能互动能够将人类意图与组织数据、工作流程和现实世界结果连接起来。BEN 的人工智能在安全的闭环环境中运行，使用经过批准的组织数据，并内置治理和合规控制。有关更多信息，请访问品牌参与网络。</p>
</div><p><strong>About Skye Salud</strong></p>
<div class="lb-trans"><p><strong>关于 Skye Salud</strong></p>
</div><p>Skye Salud is an AI-powered medical evidence platform currently under evaluation for its ability to provide evidence-based responses grounded in peer-reviewed literature, clinical guidelines and other trusted medical sources. The platform is designed to help organize and present clinical information through a conversational AI experience while maintaining transparency and traceability to supporting sources.</p>
<div class="lb-trans"><p>Skye Salud 是一个基于人工智能的医学证据平台，目前正在评估其提供基于同行评审文献、临床指南和其他可信医学来源的证据基础响应的能力。该平台旨在通过对话式人工智能体验帮助组织和呈现临床信息，同时保持对支持来源的透明性和可追溯性。</p>
</div><p><strong>About Grupo Skye</strong></p>
<div class="lb-trans"><p><strong>关于 Grupo Skye</strong></p>
</div><p>Grupo Skye is a Mexico-based AI holding company focused on executing enterprise and government AI initiatives across Latin America. It is the parent company of Skye Inteligencia LATAM and maintains an equal equity interest in Skye Salud, a healthcare-focused AI solutions company.</p>
<div class="lb-trans"><p>Grupo Skye 是一家总部位于墨西哥的人工智能控股公司，专注于在拉丁美洲执行企业和政府的人工智能项目。它是 Skye Inteligencia LATAM 的母公司，并在 Skye Salud（一家专注于医疗保健的人工智能解决方案公司）中保持平等的股权利益。</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒体联系</strong></p>
</div><p>amy@beninc.ai</p>
<div class="lb-trans"><p>amy@beninc.ai</p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>investors@beninc.ai</p>
<div class="lb-trans"><p>investors@beninc.ai</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Brand Engagement Network, Inc.'s (&#34;BEN&#34;) future financial or operating performance and may include, but are not limited to, statements regarding the anticipated capabilities, benefits, adoption, commercialization, expansion, market opportunities, and future development of Skye Salud; the expansion of condition coverage, physician adoption, and platform utilization; potential future deployments across healthcare settings, including primary care and pharmacy use cases; expansion opportunities within Mexico and Latin America; and BEN's ability to execute its growth strategy and deploy its technology in regulated industries.These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, market acceptance of BEN's products and services; the ability to successfully develop, deploy, and commercialize AI-powered solutions; customer adoption and retention; regulatory developments; competitive pressures; the availability and performance of third-party technologies and partners; general economic, business, and market conditions; and other risks described from time to time in BEN's filings with the U.S. Securities and Exchange Commission (&#34;SEC&#34;), including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. BEN undertakes no obligation to update, revise, or publicly release the results of any revision to these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明通常与未来事件或品牌参与网络公司（&#34;BEN&#34;）的未来财务或运营表现相关，可能包括但不限于关于 Skye Salud 的预期能力、好处、采用、商业化、扩展、市场机会和未来发展的声明；条件覆盖的扩展、医生的采用和平台的利用；在医疗保健环境中潜在的未来部署，包括初级护理和药房用例；在墨西哥和拉丁美洲的扩展机会；以及 BEN 执行其增长战略和在受监管行业中部署其技术的能力。这些前瞻性声明基于当前的期望、估计、预测和预测，以及管理层的信念和假设，并受到多种风险、不确定性和其他因素的影响，这些因素可能导致实际结果与这些声明所表达或暗示的结果有重大差异。这些风险和不确定性包括但不限于市场对 BEN 产品和服务的接受度；成功开发、部署和商业化基于人工智能的解决方案的能力；客户的采用和留存；监管发展；竞争压力；第三方技术和合作伙伴的可用性和表现；一般经济、商业和市场条件；以及 BEN 在美国证券交易委员会（&#34;SEC&#34;）的文件中不时描述的其他风险，包括其最近的 10-K 表格年度报告、10-Q 表格季度报告和 8-K 表格当前报告。读者被提醒不要对前瞻性声明过度依赖，这些声明仅在作出时有效。除非法律要求，BEN 没有义务更新、修订或公开发布任何对这些前瞻性声明的修订结果，以反映本新闻稿日期后的事件或情况。</p>
</div><p>SOURCE Brand Engagement Network, Inc. (BEN)</p>
<div class="lb-trans"><p>来源：品牌参与网络公司（BEN）</p>
</div>

Brand Engagement Network、Grupo Skye 和 KNOBLOCH 信息集团推动 Skye Salud 在墨西哥进入第二阶段的临床评估 | BNAI 股票新闻